Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Pollen Allergenic Extract [EPC]
Artemisia Frigida Pollen is a non-standardized allergenic extract used in the diagnosis and treatment of seasonal allergies. It belongs to the class of pollen allergenic extracts used in immunotherapy.
Name
Artemisia Frigida Pollen
Raw Name
ARTEMISIA FRIGIDA POLLEN
Category
Non-Standardized Pollen Allergenic Extract [EPC]
Drug Count
9
Variant Count
10
Last Verified
February 17, 2026
About Artemisia Frigida Pollen
Artemisia Frigida Pollen is a non-standardized allergenic extract used in the diagnosis and treatment of seasonal allergies. It belongs to the class of pollen allergenic extracts used in immunotherapy.
Detailed information about Artemisia Frigida Pollen
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Artemisia Frigida Pollen.
Artemisia Frigida Pollen, commonly known as Fringed Sagebrush or Prairie Sagewort pollen, is a biological substance used in the field of allergy and immunology. It belongs to a class of drugs called Non-Standardized Pollen Allergenic Extracts [EPC]. These extracts are derived from the pollen of the Artemisia frigida plant, a perennial subshrub native to North America and Asia. In a clinical context, this extract is utilized primarily for allergen immunotherapy (AIT), a process designed to desensitize the immune system to specific environmental triggers. Unlike standardized extracts, which are measured in Bioequivalent Allergy Units (BAU), non-standardized extracts like Artemisia Frigida are typically labeled by weight/volume (w/v) concentrations or Protein Nitrogen Units (PNU). This pharmacological agent is regulated by the FDA's Center for Biologics Evaluation and Research (CBER) and has been a cornerstone in the management of weed-induced pollinosis for decades.
At the molecular level, Artemisia Frigida Pollen extract works by modulating the patient's immune response through a process known as hyposensitization. When a patient with allergic rhinitis or asthma is exposed to this pollen, their immune system mistakenly identifies the proteins within the pollen as dangerous pathogens, triggering the production of Immunoglobulin E (IgE) antibodies. These IgE antibodies bind to mast cells and basophils. Upon subsequent exposure, the allergen cross-links these antibodies, causing the release of inflammatory mediators like histamine, leukotrienes, and cytokines, which result in the classic symptoms of hay fever.
Immunotherapy with Artemisia Frigida Pollen involves the repeated administration of the allergen in gradually increasing doses. This process induces a shift in the immune system from a Th2-cell dominated response (which promotes allergy) to a Th1-cell or T-regulatory (Treg) cell response. This shift leads to the production of 'blocking antibodies,' specifically IgG4, which compete with IgE for allergen binding sites. Over time, this reduces the activation of mast cells and decreases the recruitment of eosinophils to the respiratory mucosa, effectively raising the threshold at which the patient experiences allergic symptoms.
Artemisia Frigida Pollen extract is FDA-approved for the following indications:
Off-label uses are rare, though some clinicians may use these extracts in experimental protocols for sublingual immunotherapy (SLIT) if a standardized version is unavailable, though this is not the primary intended use for most non-standardized injectable extracts.
Artemisia Frigida Pollen is most commonly available in the following forms:
> Important: Only your healthcare provider can determine if Artemisia Frigida Pollen is right for your specific condition. The complexity of immunotherapy requires expert supervision by an allergist or immunologist.
Dosage for Artemisia Frigida Pollen immunotherapy is highly individualized and must be determined by a specialist based on the patient's sensitivity levels. The treatment is divided into two distinct phases:
During this phase, the patient receives injections once or twice weekly. The starting dose is typically a very low concentration (e.g., 0.05 mL of a 1:100,000 w/v dilution). The dose is gradually increased by 20% to 50% at each visit, provided the patient tolerates the previous dose without a significant local or systemic reaction. This phase usually lasts 3 to 6 months.
Once the 'effective dose' or 'top dose' is reached (often 0.5 mL of a 1:20 or 1:10 w/v concentration), the frequency of injections is decreased to once every 2 to 4 weeks. Maintenance therapy is typically continued for 3 to 5 years to ensure long-term immunological tolerance.
Artemisia Frigida Pollen is generally considered safe for use in children, typically starting around age 5. Younger children may be treated if the benefit outweighs the risk of the child's inability to communicate symptoms of a systemic reaction. The dosing schedule for children follows the same escalation logic as adults but may start at even lower concentrations depending on the child's skin test reactivity and clinical history. There is no specific 'weight-based' calculation; rather, it is 'reactivity-based.'
No specific dose adjustments are required for patients with renal impairment, as the extract is not nephrotoxic. However, patients with severe renal disease may have a reduced capacity to clear the mediators released during an accidental anaphylactic event.
No adjustments are necessary for hepatic impairment, as the liver does not play a significant role in the metabolism of allergenic proteins.
Caution is advised for patients over age 65. Older adults are more likely to have underlying cardiovascular disease, which can make the use of epinephrine (the treatment for a severe reaction) more dangerous. The starting dose may be more conservative in this population.
Artemisia Frigida Pollen extracts are administered via subcutaneous injection, usually in the posterior aspect of the upper arm.
If a dose is missed during the build-up phase, the next dose may need to be reduced or the previous dose repeated, depending on how much time has passed. If a dose is missed during the maintenance phase:
An 'overdose' in the context of immunotherapy usually refers to an accidental administration of a concentration higher than the patient's current tolerance level. Signs include rapid onset of hives, swelling of the throat, wheezing, and drop in blood pressure. Emergency measures include the immediate administration of intramuscular epinephrine, antihistamines, and potentially corticosteroids. Healthcare settings where these injections are given must be equipped with a 'crash cart' and oxygen.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or frequency without medical guidance. Immunotherapy is a long-term commitment that requires strict adherence to the schedule.
Most patients undergoing immunotherapy with Artemisia Frigida Pollen will experience local reactions at the site of injection. These are generally not dangerous but can be uncomfortable.
These reactions are systemic but usually mild to moderate in severity.
> Warning: Stop taking Artemisia Frigida Pollen and call your doctor immediately or seek emergency care if you experience any of these symptoms of anaphylaxis.
There are few documented long-term negative side effects of Artemisia Frigida Pollen when administered correctly. The primary long-term 'effect' is the desired modification of the immune system. However, some patients may develop a persistent nodule (granuloma) at the injection site if the extract is injected too superficially or if the patient has a reaction to the aluminum salts sometimes used as adjuvants in certain formulations.
Artemisia Frigida Pollen extracts carry a class-wide warning regarding the risk of severe non-standardized allergenic reactions.
Report any unusual symptoms to your healthcare provider. Even a 'mild' systemic reaction like a few hives should be reported, as it may predict a more severe reaction at the next dose.
Artemisia Frigida Pollen is a potent biological product. It is not a 'vaccine' in the traditional sense of preventing infection, but rather a tool for immune modification. Safety depends entirely on the precision of the dose and the clinical stability of the patient on the day of the injection. Patients should never receive an injection if they are currently experiencing an acute asthma flare or a significant fever.
No specific individual black box warning exists for Artemisia Frigida Pollen specifically, but it falls under the general FDA mandate for all allergenic extracts. The warning emphasizes that these products can cause severe, life-threatening systemic reactions, including anaphylaxis. It states that the product must be administered in a facility equipped to handle respiratory and cardiac emergencies and that patients must be observed for at least 30 minutes post-dose.
Generally, Artemisia Frigida Pollen does not cause drowsiness. However, if a patient experiences a mild systemic reaction or receives an antihistamine as a premedication, their ability to drive may be impaired. Patients should ensure they feel completely normal before leaving the clinic.
Alcohol consumption should be avoided for several hours before and after an injection. Alcohol causes vasodilation (widening of blood vessels), which can increase the rate of allergen absorption from the injection site and potentially increase the risk or severity of a systemic reaction.
If a patient experiences a severe systemic reaction, the healthcare provider will conduct a risk-benefit analysis. In some cases, the concentration is reduced, and the build-up is attempted again more slowly. In other cases, the treatment is discontinued permanently. There is no 'withdrawal syndrome' associated with stopping allergenic extracts, but the patient's allergy symptoms will likely return over time if the maintenance phase was not completed.
> Important: Discuss all your medical conditions with your healthcare provider before starting Artemisia Frigida Pollen. Be honest about your recent health history at every appointment.
For each major interaction, the mechanism typically involves either pharmacodynamic interference (blocking the rescue medication) or a lowering of the physiological threshold for mast cell degranulation. Management involves careful screening of the patient's medication list before starting therapy and potentially switching to alternative blood pressure medications (like ARBs) if immunotherapy is deemed essential.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter eye drops and cold medicines.
Artemisia Frigida Pollen must NEVER be used in the following circumstances:
Conditions requiring careful risk-benefit analysis include:
Patients allergic to Artemisia frigida often show cross-sensitivity to other members of the Asteraceae family. This includes:
If a patient has had a severe reaction to a Ragweed extract, the clinician should be extremely cautious when initiating Artemisia Frigida Pollen, as the shared proteins (like Art v 1) may trigger a similar response.
> Important: Your healthcare provider will evaluate your complete medical history and perform a physical exam before prescribing Artemisia Frigida Pollen to ensure it is safe for you.
Artemisia Frigida Pollen is classified as FDA Pregnancy Category C.
It is not known whether the allergenic components of Artemisia Frigida Pollen are excreted in human milk. However, because these are large proteins that are likely broken down in the mother's digestive tract if ingested, and the amount injected is miniscule, the risk to a nursing infant is considered negligible. Immunotherapy is generally considered compatible with breastfeeding.
Patients with chronic kidney disease (CKD) can receive Artemisia Frigida Pollen. There is no evidence of accumulation of the extract in renal tissue. The primary concern is the patient's overall physiological resilience in the event of an emergency.
There are no specific restrictions for patients with liver disease. The processing of allergenic proteins is a proteolytic process occurring in the blood and tissues, not a hepatic metabolic process.
> Important: Special populations require individualized medical assessment. Always inform your allergist if you become pregnant or develop new health conditions during the course of your treatment.
Artemisia Frigida Pollen extract acts as an immunomodulator. The primary allergens in the pollen (proteins such as Art f 1) are recognized by Antigen Presenting Cells (APCs), such as dendritic cells. In an allergic individual, these APCs normally prime T-cells to become Th2 cells, which secrete IL-4 and IL-13, leading to IgE production.
Immunotherapy changes this process by:
| Parameter | Value |
|---|---|
| Bioavailability | N/A (Biological extract, local absorption) |
| Protein Binding | Minimal (Proteins are degraded rather than bound) |
| Half-life | Variable (Proteins: hours; Immunological effect: years) |
| Tmax | 1 - 4 hours (for systemic absorption of proteins) |
| Metabolism | Proteolysis (Extracellular and intracellular) |
| Excretion | Renal (as small peptide fragments) |
Artemisia Frigida Pollen is classified as a Non-Standardized Pollen Allergenic Extract. It is part of the broader category of 'Biologicals' and 'Allergenics.' Related medications include Mugwort (Artemisia vulgaris) extracts and Ragweed (Ambrosia) extracts.
Common questions about Artemisia Frigida Pollen
Artemisia Frigida Pollen is used as an allergenic extract for the diagnosis and treatment of seasonal allergies caused by the Fringed Sagebrush plant. In diagnostic settings, it is used in skin tests to confirm if a patient is allergic to this specific weed. In treatment, it is used in allergen immunotherapy (allergy shots) to gradually desensitize the immune system. This helps reduce symptoms of allergic rhinitis, conjunctivitis, and seasonal asthma. It is specifically indicated for patients whose symptoms are not well-controlled by standard medications like antihistamines.
The most common side effects are local reactions at the site of the injection, occurring in nearly all patients at some point during therapy. These include redness, itching, and swelling (a 'wheal') where the shot was given. These reactions typically appear within minutes and resolve within 24 hours. Some patients may also experience mild systemic symptoms like increased sneezing or tiredness on the day of the injection. While most side effects are minor, the risk of a severe allergic reaction (anaphylaxis) is always present, which is why shots are given in a doctor's office.
It is generally advised to avoid alcohol for several hours before and after receiving an injection of Artemisia Frigida Pollen. Alcohol causes blood vessels to dilate (expand), which can speed up the absorption of the pollen extract into your bloodstream. This rapid absorption can increase the risk of a systemic allergic reaction or make a reaction more severe. Additionally, alcohol can interfere with your ability to recognize early symptoms of a reaction. Always follow the specific safety guidelines provided by your allergist regarding lifestyle restrictions.
Artemisia Frigida Pollen is generally not started during pregnancy because the 'build-up' phase carries a higher risk of systemic reactions, which could harm the fetus by reducing oxygen supply. However, if a woman is already on a stable maintenance dose and becomes pregnant, most allergists recommend continuing the treatment. The maintenance dose is unlikely to cause a new reaction and helps keep the mother's allergy and asthma symptoms under control. Decisions regarding immunotherapy during pregnancy should be made through a careful discussion between the patient, their allergist, and their obstetrician.
Immunotherapy with Artemisia Frigida Pollen is a slow process and does not provide immediate relief like an antihistamine. Most patients begin to notice a significant improvement in their allergy symptoms after 6 to 12 months of consistent treatment, usually once they have reached the maintenance dose. The full benefits are typically realized after the second year of therapy. For the best long-term results, the treatment is usually continued for a total of three to five years. Skipping doses or stopping early can result in the return of allergy symptoms.
Yes, you can stop taking Artemisia Frigida Pollen injections suddenly without experiencing a 'withdrawal' effect like you might with some other medications. There are no physical dependencies associated with allergenic extracts. However, stopping the treatment before the recommended 3-5 year course is complete will likely result in the gradual return of your allergy symptoms. If you need to stop due to side effects or life changes, discuss a plan with your doctor. They can advise you on whether a shorter course has provided any lasting benefit.
If you miss a dose of Artemisia Frigida Pollen, you should contact your allergist's office as soon as possible to reschedule. Do not simply wait until your next scheduled appointment. The safety of the next dose depends on the timing; if too much time has passed since your last injection, your immune system's tolerance may have decreased. Your doctor may need to repeat your last dose or even reduce the dose to prevent a reaction. Never attempt to 'double up' on doses to make up for a missed one.
There is no scientific evidence to suggest that Artemisia Frigida Pollen or other allergenic extracts cause weight gain. These extracts are biological proteins administered in very small quantities and do not affect the metabolic processes or hormones associated with weight regulation. If you experience weight changes while on immunotherapy, they are likely due to other factors such as lifestyle changes, other medications (like oral steroids for asthma), or unrelated medical conditions. Discuss any concerns about weight with your primary care physician.
Artemisia Frigida Pollen can be taken alongside most common medications, but there are critical exceptions. You must inform your doctor if you are taking beta-blockers (for heart issues or glaucoma), as these can make it difficult to treat a severe allergic reaction. ACE inhibitors and certain antidepressants may also interact with how your body handles a reaction. Most standard allergy medications, like nasal sprays and antihistamines, are safe and often encouraged to manage symptoms during the build-up phase. Always provide your allergist with a complete list of your current medications.
Artemisia Frigida Pollen is a biological product rather than a chemically synthesized drug, so the term 'generic' does not apply in the traditional sense. Instead, various manufacturers produce their own versions of the extract, which are considered 'non-standardized allergenic extracts.' While different brands may be used, they are not always perfectly interchangeable because the manufacturing processes can vary. Your allergist will typically stick with one manufacturer's extract for the duration of your treatment to ensure consistent dosing and potency.